Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorEzelsoy, M.
dc.contributor.authorSaracoglu, K.T.
dc.contributor.authorOral, K.
dc.contributor.authorSaracoglu, A.
dc.contributor.authorAkpinar, B.
dc.date.accessioned2020-12-02T18:00:11Z
dc.date.available2020-12-02T18:00:11Z
dc.date.issued2020
dc.identifier.issn0102-7638
dc.identifier.urihttps://doi.org/10.21470/1678-9741-2019-0360
dc.identifier.urihttp://hdl.handle.net/11446/3554
dc.description.abstractIntroduction: Heparin-induced thrombocytopenia (HIT) is a potentially lethal complication of unfractionated or low-molecular weight heparin therapy. We aimed to determine the incidence and mortality rate of patients with positive heparin/platelet factor 4 (PF4) antibodies, which is a rapid detection test of HIT. Methods: Coronary artery bypass grafting and mitral and aortic valve surgeries were evaluated. Cardiopulmonary bypass was employed in all patients. the diagnosis of HIT was based on immunological assays. Postoperative complications, mortality rates, and the causes of death were specified in patients with positive heparin/PF4 antibodies. Results: Postoperative thrombocytopenia was detected in 257 patients. Twenty of these patients undergoing open heart surgery were included in the final analysis. Antibodies against heparin/PF4 complex were positive in 20 patients. the mean body mass index was 28.8±2.3 kg/m², mean value of left ventricular ejection fraction was 48.3±6.7%, cardiopulmonary bypass time was 113.0±35.0 min, aortic cross-clamping time was 88.0±32.7 min, mean intensive care unit length of stay was 10.9±4.9 days, mean preoperative platelet count was 307.250±88528 platelets/microliter, and mean postoperative platelet count was 243.050±89.354 platelets/ microliter. the mean duration of heparin exposure was 6.9±2.9 days. the mortality rate was 45% (nine patients) and 1.2% (three patients) in heparin/PF4 complex positive and negative patients, respectively. Conclusion: Although the incidence of HIT was low in patients undergoing open heart surgery, an increased rate of early mortality was observed in patients with positive heparin/PF4 antibodies. © 2020, Sociedade Brasileira de Cirurgia Cardiovascular. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherSociedade Brasileira de Cirurgia Cardiovascularen_US
dc.identifier.doi10.21470/1678-9741-2019-0360en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAortic Valveen_US
dc.subjectCardiopulmonary Bypassen_US
dc.subjectCause of Deathen_US
dc.subjectHeparin-adverse effectsen_US
dc.subjectIncidenceen_US
dc.subjectThrombocytopeniaen_US
dc.titlePositive heparin/pf4 antibodies and high mortality rate: A retrospective case-series analysisen_US
dc.typearticleen_US
dc.relation.journalBrazilian Journal of Cardiovascular Surgeryen_US
dc.departmentDBÜen_US
dc.identifier.issue6en_US
dc.identifier.volume35en_US
dc.identifier.startpage950en_US
dc.identifier.endpage957en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-tempEzelsoy, M., Department of Cardiovascular Surgery, Istanbul Demiroglu Bilim University Medical School, Istanbul, Turkey; Saracoglu, K.T., Department of Anesthesiology and Intensive Care, Health Sciences University Medical School, Istanbul, Turkey; Oral, K., Department of Cardiovascular Surgery, Istanbul Demiroglu Bilim University Medical School, Istanbul, Turkey; Saracoglu, A., Department of Anesthesiology and Intensive Care, Istanbul Marmara University Medical School, Istanbul, Turkey; Akpinar, B., Department of Cardiovascular Surgery, Istanbul Demiroglu Bilim University Medical School, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster